| Name | Title | Contact Details |
|---|
Meet Twiage: An award-winning mobile communication technology that enables hospitals and EMS to accelerate life-saving emergency care by reducing the need of radio and phone communication. Twiage offers Hospitals & Emergency Departments: - Real-time prehospital clinical data for Stroke, STEMI, Trauma, and Sepsis, as well as all other EMS transports - HIPAA-compliant Videos, Photos, and EKGs - Patient Pre-Registration - GPS-tagged ETA for every incoming ambulance, optimizing ED flow and triage - Two-way communication capabilities for intra-hospital care coordination and inter-facility transfers. Twiage offers EMS: - Faster handoffs and ED turnaround times - No more reliance on radios! - HIPAA-compliant video, photos, and data capture sent directly to entire hospital teams - Simple, evidence-driven algorithms that help improve quality handoffs - Ability to create custom algorithms to match your clinical protocols Awards: Pulse @ MassChallenge, Platinum Award, 2017 MATTER Chicago, Observation Unit Challenge - Winner, 2017 American Heart/Stroke Association, Health Tech Competition - People`s Choice Award, 2016 American Medical Association, Healthier Nation Challenge - 1st Place Winner, 2016 Aspen Institute, Spotlight Health Finalist, 2016 Cornell Venture Challenge - 2nd Place Winner, 2016 Cleveland Clinic, New Ventures Healthcare Challenge - Winner, 2015 Massachusetts Medical Society, Information Technology Award, 2014 mHealth, Rockstar of the Year for most meaningful mobile health technology, 2014
Medisiss is a Redmond, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Haworth Cleaners is a Haworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nutracea, Inc. is a Paradise Valley, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.